




## Innovations in Hypertension Management: Direct renin inhibition ~ David Fitchett





### Summary of aliskiren preclinical data

- Aliskiren demonstrates organ protective effects in animal models
  - Renoprotection comparable to ACEi and ARBs
  - LVH reductions comparable to ARBs
  - Atherogenesis prevention
- Aliskiren may affect the renin receptor (pathophysiological relevance of (pro)renin receptor still unknown...)
  - Upcoming preclinical studies will address key questions such as :
    - Does the (pro)renin receptor play a role in pathogenesis of CV disease ?
    - What is the effect of aliskiren on (pro)renin receptor function ?
    - Can aliskiren block the enzymatic activity of (pro)renin ?



## Innovations in Hypertension Management: Direct renin inhibition ~ David Fitchett



### Aliskiren is an effective antihypertensive due to direct renin inhibition

- Monotherapy provides double-digit BP reductions
- Consistent additive BP lowering
- Superior BP reductions versus ACEi
- Durability and persistence of control; no rebound